The clinical response to vemurafenib in a patient with a rare BRAF V600DK601del mutation-positive melanoma

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

(2013) L Heinzerling et al.   BRITISH JOURNAL OF CANCER

The somatic affairs ofBRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations

(2013) Giovanni Ponti et al.   JOURNAL OF CLINICAL PATHOLOGY

Identification of a Novel ComplexBRAFMutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma

(2013) Benoit Busser et al.   JAMA Dermatology

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma

(2012) Steven Anderson et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase

(2012) Li Ren et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications

(2012) F. Sclafani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

BRAF inhibitor activity in V600R metastatic melanoma

(2012) Oliver Klein et al.   EUROPEAN JOURNAL OF CANCER

Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

(2012) Wesley O. Greaves et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

(2012) Christine M. Lovly et al.   PLoS One

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplex Mutation Screening by Mass Spectrometry

(2011) Carol Beadling et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE